Pure Red Cell Aplasia Treatment & Management
- Author: Paul Schick, MD; Chief Editor: Emmanuel C Besa, MD more...
The initial treatment plan should include transfusions for patients who are severely anemic and have cardiorespiratory failure. Anemia is more severe in patients with pure red cell aplasia (PRCA) who have ongoing hemolysis (aplastic crises).
Medications that could cause PRCA should be discontinued.
Children with PRCA should be observed and not aggressively treated to avoid corticosteroid-related growth retardation. This caution is feasible since PRCA in children is often transient and reversible. However, transfusion should be administered if indicated.
Infections should be treated. High-dose intravenous immunoglobin therapy should be considered for parvovirus B19 infections. PRCA due to medication or infections is usually reversible within a few months, if not earlier. However, immunotherapy may be needed to reverse erythropoiesis-stimulating agent (ESA)–related PRCA.
Underlying conditions should be treated. These conditions include a thymoma, hematological malignancies such as T-cell large granular lymphocyte leukemia, solid tumors, and systemic lupus erythematosus (SLE). Surgery or gamma irradiation of the thymus should be considered in a patient with a thymoma.
PRCA considered to be idiopathic and due to autoimmunity should be initially treated with corticosteroids.[1, 2, 24] A response is expected within 4-6 weeks in about 45% of patients. Corticosteroids should be judiciously given to children to avoid growth retardation. Immunosuppressive agents have an important role. Immunosuppressive agents used in PRCA include cyclophosphamide, 6-mercaptopurine, azathioprine, and cyclosporine A. Rituximab has been reported to be effective in managing PRCA.[29, 30, 25, 31] Antithymic globulin (ATG) is another therapeutic option. Danazol has been helpful in some cases but is contraindicated in children. Plasmapheresis has been used to remove autoantibodies.
Autologous and nonmyeloablative allogeneic peripheral stem cell transplantation have been used, especially in patients refractory to therapy.
Several patients have responded to plasmapheresis or lymphocytapheresis.
Iron chelation should be considered in patients who have had multiple transfusions and have evidence of iron overload.
Thymectomy might be indicated in patients with a thymoma. However, the procedure should not be performed in patients with a normal-sized thymus. About 30% of patients with thymomas respond to thymectomy.
Although not effective in most cases, splenectomy might be helpful in refractory cases. Splenectomy is indicated to manage pure red cell aplasia (PRCA) complicated by hypersplenism.
Consultations with a hematologist and rheumatologist are indicated. A hematologist should be consulted for the diagnosis and management of pure red cell aplasia (PRCA). A rheumatologist should be consulted in patients with autoimmune disorders.
Activity might be limited in anemic patients.
Further inpatient care and outpatient care
The goals of inpatient care are to diagnose pure red cell aplasia (PRCA) and any underlying disorders, initiate appropriate management, monitor the response to therapy, and manage the adverse effects of therapy.
Avoid medications that might cause pure red cell aplasia (PRCA).
Severe uncompensated anemia can cause myocardial damage and organ failure.
Multiple transfusions can cause hemosiderosis.
Corticosteroid therapy can cause osteopenia, osteoporosis, and growth retardation.
Patients who are on immunosuppressive therapy can develop an acute leukemia and aplastic anemia.
The possibility exists for the transmission of infections by transfusion therapy, intravenous immunoglobulin G, and antilymphocytic serum.
The consequences of iron overload due to multiple transfusions should be explained.
The possibility of the transmission of infections by transfusion therapy, intravenous immunoglobulin G, and antilymphocytic serum should be explained.
The adverse effects of corticosteroids, immunotherapy, and other aspects of management should be explained.
Hoffman R, Benz EJ, Furie B, Shattil SJ. Hematology: Basic Principles and Practice. Philadelphia, Pa: Churchill Livingstone; 2009.
Kaushansky, Kenneth, Lichtman Marshall A, Beutler, Ernest , et al. Williams Hematology. Eighth Edition. McGraw-Hill Professional; 2010.
Van Hook JW, Gill P, Cyr D, Kapur RP. Diamond-Blackfan anemia as an unusual cause of nonimmune hydrops fetalis: a case report. Reprod Med. 40:850-854. [Medline].
Hirokawa M. RPS19 mutations in patients with Diamond-Blackfan anemia. Br J Haematol. 2008. 142:911-20.
Morimoto K, Lin S, Sakamoto K. The functions of RPS19 and their relationship to Diamond-Blackfan anemia: a review. Mol Genet Metab. 2007 Apr. 90(4):358-62. [Medline].
Boultwood J, Yip BH, Vuppusetty C, Pellagatti A, Wainscoat JS. Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies. Adv Biol Regul. 2013 Jan. 53(1):8-17. [Medline].
Boultwood J, Pellagatti A, Wainscoat JS. Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome. Adv Biol Regul. 2012 Jan. 52(1):196-203. [Medline].
Ellis SR, Gleizes PE. Diamond Blackfan anemia: ribosomal proteins going rogue. Semin Hematol. 2011 Apr. 48(2):89-96. [Medline].
Garçon L, Ge J, Manjunath SH, Mills JA, Apicella M, Parikh S. Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients. Blood. 2013 Aug 8. 122(6):912-21. [Medline].
Cherrick I, Karayalcin G, Lanzkowsky P. Transient erythroblastopenia of childhood. Prospective study of fifty patients. Am J Pediatr Hematol Oncol. 1994 Nov. 16(4):320-4. [Medline].
Baker RI, Manoharan A, de Luca E, Begley CG. Pure red cell aplasia of pregnancy: a distinct clinical entity. Br J Haematol. 1993 Nov. 85(3):619-22. [Medline].
Bierman PJ, Warkentin P, Hutchins MR, Klassen LW. Pure red cell aplasia following ABO mismatched marrow transplantation for chronic lymphocytic leukemia: response to antithymocyte globulin. Leuk Lymphoma. 1993 Jan. 9(1-2):169-71. [Medline].
Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15. 106(10):3343-7. [Medline]. [Full Text].
Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant. 2003 Nov. 18 Suppl 8:viii37-41. [Medline].
Liu Z, Stoll VS, Devries PJ, Jakob CG, Xie N, Simmer RL, et al. A potent erythropoietin-mimicking human antibody interacts through a novel binding site. Blood. 2007 Oct 1. 110(7):2408-13. [Medline].
al-Awami Y, Sears DA, Carrum G, Udden MM, Alter BP, Conlon CL. Pure red cell aplasia associated with hepatitis C infection. Am J Med Sci. 1997 Aug. 314(2):113-7. [Medline].
Tomida S, Matsuzaki Y, Nishi M, Ikegami T, Chiba T, Abei M, et al. Severe acute hepatitis A associated with acute pure red cell aplasia. J Gastroenterol. 1996 Aug. 31(4):612-7. [Medline].
Herbert KE, Prince HM, Westerman DA. Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood. 2003. 101:1654.
Ahsan N, Holman MJ, Gocke CD, Groff JA, Yang HC. Pure red cell aplasia due to parvovirus B19 infection in solid organ transplantation. Clin Transplant. 1997 Aug. 11(4):265-70. [Medline].
Smalling R, Foote M, Molineux G, Swanson SJ, Elliott S. Drug-induced and antibody-mediated pure red cell aplasia: a review of literature and current knowledge. Biotechnol Annu Rev. 2004. 10:237-50. [Medline].
Thompson DF, Gales MA. Drug-induced pure red cell aplasia. Pharmacotherapy. 1996 Nov-Dec. 16(6):1002-8. [Medline].
Li G, Li ZQ, Yang QY, Yang JD. Acquired pure red cell aplasia due to treatment with clopidogrel: first case report. J Thromb Thrombolysis. 2013 Dec 3. [Medline].
Gupta R, Ezeonyeji A, Thomas A, Scully M, Ehrenstein M, Isenberg D. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: Responseto rituximab and cyclophosphamide. Lupus. 2011. 20(14):1547-1550. [Medline].
Wong S, Brown KE. Development of an improved method of detection of infectious parvovirus B19. J Clin Virol. 2006 Apr. 35(4):407-13. [Medline].
Björkholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders. J Intern Med. 1993 Aug. 234(2):119-26. [Medline].
Dhodapkar MV, Lust JA, Phyliky RL. T-cell large granular lymphocytic leukemia and pure red cell aplasia in a patient with type I autoimmune polyendocrinopathy: response to immunosuppressive therapy. Mayo Clin Proc. 1994 Nov. 69(11):1085-8. [Medline].
Helbig G, Stella-Holowiecka B, Krawczyk-Kulis M, Wojnar J, Markiewicz M, Wojciechowska-Sadus M. Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia. Haematologica. 2005 Nov. 90 Suppl:ECR33. [Medline].
D'Arena G, Vigliotti ML, Dell'Olio M, Villa MR, Mantuano S, Scalzulli PR, et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol. 2009 Mar. 82(3):235-9. [Medline].
Viviano KR, Webb JL. Clinical use of cyclosporine as an adjunctive therapy in the management of feline idiopathic pure red cell aplasia. J Feline Med Surg. 2011 Dec. 13(12):885-95. [Medline].
Passweg JR, Rabusin M, Musso M, Beguin Y, Cesaro S, Ehninger G, et al. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol. 2004 Jun. 125(6):749-55. [Medline].
Musso M, Porretto F, Crescimanno A, Polizzi V, Scalone R. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and nonmyeloablative allogeneic peripheral stem cell transplantation. Bone Marrow Transplant. 2004 Apr. 33(7):769-71. [Medline].